Issue of Equity, TVRs & PDMR Dealing

RNS Number : 2507L

Instem plc

17 July 2017

 

Instem plc
("Instem" or the "Company")

Issue of Equity, Total Voting Rights and PDMR Dealing

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that, following the exercise of vested EMI share options by an employee, 1,500 ordinary shares of 10p each in the Company ("Ordinary Shares") have been issued.

Application will be made to the London Stock Exchange for the admission of the 1,500 new Ordinary Shares to trading on AIM. Admission is expected to take place at 8.00am on 19 July 2017.

Total Voting Rights

Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 15,866,660 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 15,866,660.

The figure of 15,866,660 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

PDMR Dealing

The Company was notified on 13 July that on 12 July 2017, the DG 2008 Discretionary Settlement (of which David Gare (the Company chairman) and his wife are the trustees) transferred 10,000 Ordinary Shares to David's son Adrian Gare and a further 10,000 to his daughter, Debbie Walker, for nil consideration. Following the transaction, the DG 2008 Discretionary Settlement now has a total interest in 1,398,427 Ordinary Shares, representing approximately 8.81% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	David Gare (via the DG 2008 Discretionary Settlement)
2	Reason for the notification
a)	Position/status	Chairman of the Company
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Instem plc
b)	LEI	213800PILYUFNNROQX68
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 10p each
	Identification code	GB00B3TQCK30
b)	Nature of the transaction	Transfer of ordinary shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			0p	10,000
d)	Aggregated information
	- Aggregated volume	N/A
	- Price
e)	Date of the transaction	12 July 2017
f)	Place of the transaction	London Stock Exchange (XLON)
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 10p each
	Identification code	GB00B3TQCK30
b)	Nature of the transaction	Transfer of ordinary shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			0p	10,000
d)	Aggregated information
	- Aggregated volume	N/A
	- Price
e)	Date of the transaction	12 July 2017
f)	Place of the transaction	London Stock Exchange (XLON)

For further information, please contact:

Instem plc	[phone]
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser & Broker)	[phone]
Richard Lindley James White
Walbrook Financial PR	[phone]
Paul Cornelius	[e-mail]
Helen Cresswell Sam Allen Paul Whittington

About Instem 

Instem is a leading supplier of IT applications and services to the early development healthcare market delivering compelling solutions for data collection, analysis and regulatory submissions management. Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India. 

To learn more about Instem solutions and its mission, please visit www.instem.com

 

END

 

 

IOEBGGDRLDBBGRR